These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 1950028)

  • 21. Prevention of NSAID-induced GI mucosal injury.
    Gerritz S; Newton WP
    J Fam Pract; 1997 Feb; 44(2):130-1. PubMed ID: 9040509
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial].
    Karateev AE; Nasonov EL; Radenska-Lopovok SG
    Ter Arkh; 2005; 77(2):46-9. PubMed ID: 15807452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carprofen and the therapy of gastroduodenal ulcerations by ranitidine.
    Czarnobilski Z; Bem S; Czarnobilski K; Konturek SJ
    Hepatogastroenterology; 1985 Feb; 32(1):20-3. PubMed ID: 3872836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs.
    ten Wolde S; Dijkmans BA; Janssen M; Hermans J; Lamers CB
    Aliment Pharmacol Ther; 1996 Jun; 10(3):347-51. PubMed ID: 8791962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S.E.M. study II: Protective effect of ranitidine against gastric and duodenal lesions induced by non-steroidal anti-inflammatory drugs.
    Zoli G; Pasquinelli G; Bonvicini F; Gasbarrini G; Laschi R
    Int J Tissue React; 1986; 8(1):71-7. PubMed ID: 3949446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevention and therapy of NSAID-induced ulcers: fact versus myth].
    Fried M; Bertschinger P
    Schweiz Med Wochenschr; 1996 Sep; 126(37):1569-72. PubMed ID: 8927961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.
    Larkai EN; Smith JL; Lidsky MD; Graham DY
    Am J Gastroenterol; 1987 Nov; 82(11):1153-8. PubMed ID: 3499815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The endoscopic assessment of the effect of ranitidine and pirenzepine on the manifestations of the gastropathy induced by nonsteroidal anti-inflammatory preparations].
    Karateev AE; Murav'ev IuV; Nasonova VA
    Ter Arkh; 1997; 69(5):67-9. PubMed ID: 9235663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Helicobacter pylori eradication may reduce the risk of gastroduodenal lesions in chronic NSAID users.
    Russell RI
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):465-9. PubMed ID: 9494858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy.
    Yeomans ND
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S89-92. PubMed ID: 10379475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatories and gastroduodenal damage: therapeutic options.
    Agrawal NM
    Eur J Rheumatol Inflamm; 1993; 13(1):17-24. PubMed ID: 7821335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development and relapse of gastroduodenal ulcer in patients taking nonsteroid anti-inflammatory drugs: effects of standard risk factors].
    Karateev AE; Nasonova VA
    Ter Arkh; 2008; 80(5):62-6. PubMed ID: 18590118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.
    Ehsanullah RS; Page MC; Tildesley G; Wood JR
    BMJ; 1988 Oct; 297(6655):1017-21. PubMed ID: 3142593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymptomatic and symptomatic gastroduodenal patients affected by rheumatic disease treated with non-steroidal anti-inflammatory drugs.
    Magarò M; Altomonte L; Zoli A; Mirone L; Berchicci MC; Tricerri A; Corvino G
    Panminerva Med; 1989; 31(1):16-8. PubMed ID: 2786181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
    Campbell DR; Haber MM; Sheldon E; Collis C; Lukasik N; Huang B; Goldstein JL
    Am J Gastroenterol; 2002 Sep; 97(9):2208-14. PubMed ID: 12358234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of quadruple therapy in the eradication of Helicobacter pylori and prevention of recurrent duodenal ulcer].
    Ocaña Andrade E; Espinosa Soberanes JA; Mares Zambrano MA; Rosete Reyes A
    Rev Gastroenterol Mex; 1998; 63(4):182-6. PubMed ID: 10319667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of pepsinogen I in serum as a screening method for early detection of gastroduodenal lesions and follow-up in therapy with non-steroidal antirheumatic drugs].
    Kullich W; Pöllmann G; Zmerekar C; Klein G
    Z Rheumatol; 1991; 50(1):39-45. PubMed ID: 2058321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.